CSTL Castle Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSTL

Price (delayed)

$24.33

Market cap

$671.68M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.14

Enterprise value

$613.79M

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently ...

Highlights
The gross profit has soared by 74% YoY and by 16% from the previous quarter
CSTL's revenue has soared by 65% YoY and by 14% from the previous quarter
The debt has soared by 94% YoY and by 64% QoQ
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.castlebiosciences.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of CSTL
Market
Shares outstanding
27.61M
Market cap
$671.68M
Enterprise value
$613.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.66
Price to sales (P/S)
2.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.45
Earnings
Revenue
$250.73M
EBIT
-$30.64M
EBITDA
-$17.87M
Free cash flow
-$6.44M
Per share
EPS
-$1.14
Free cash flow per share
-$0.23
Book value per share
$14.66
Revenue per share
$9.12
TBVPS
$12.49
Balance sheet
Total assets
$458.51M
Total liabilities
$56.05M
Debt
$25.05M
Equity
$402.46M
Working capital
$263.82M
Liquidity
Debt to equity
0.06
Current ratio
9.25
Quick ratio
8.85
Net debt/EBITDA
3.24
Margins
EBITDA margin
-7.1%
Gross margin
80.6%
Net margin
-12.3%
Operating margin
-16.7%
Efficiency
Return on assets
-6.9%
Return on equity
-7.9%
Return on invested capital
-14.4%
Return on capital employed
-7.2%
Return on sales
-12.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
6.52%
1 week
19.62%
1 month
13.01%
1 year
6.2%
YTD
12.74%
QTD
9.84%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$250.73M
Gross profit
$202.03M
Operating income
-$41.93M
Net income
-$30.8M
Gross margin
80.6%
Net margin
-12.3%
The operating margin has surged by 75% year-on-year and by 46% since the previous quarter
The net margin has soared by 74% YoY and by 53% QoQ
The gross profit has soared by 74% YoY and by 16% from the previous quarter
CSTL's revenue has soared by 65% YoY and by 14% from the previous quarter

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
P/E
N/A
P/B
1.66
P/S
2.67
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.45
CSTL's EPS has surged by 58% year-on-year and by 47% since the previous quarter
CSTL's price to book (P/B) is 46% lower than its 5-year quarterly average of 3.1 but 28% higher than its last 4 quarters average of 1.3
The equity is up by 4.5% year-on-year and by 2.9% since the previous quarter
The P/S is 73% below the 5-year quarterly average of 9.8 but 11% above the last 4 quarters average of 2.4
CSTL's revenue has soared by 65% YoY and by 14% from the previous quarter

Efficiency

How efficient is Castle Biosciences business performance
CSTL's return on sales has surged by 75% year-on-year and by 53% since the previous quarter
Castle Biosciences's return on invested capital has surged by 73% YoY and by 52% QoQ
Castle Biosciences's return on assets has surged by 57% YoY and by 48% QoQ
The ROE has soared by 55% YoY and by 47% QoQ

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
CSTL's current ratio is up by 49% since the previous quarter and by 2.9% year-on-year
Castle Biosciences's quick ratio has increased by 49% QoQ and by 2.2% YoY
The debt is 94% lower than the equity
CSTL's debt to equity has surged by 100% year-on-year and by 50% since the previous quarter
The debt has soared by 94% YoY and by 64% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.